645TiP TALAPRO-3: A phase III, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients (pts) with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC)

Abstract

TALA is a poly (ADP-ribose) polymerase inhibitor (PARPi) approved as monotherapy for germline BRCA1/2-mutated HER2-negative advanced breast cancer. PARPi have demonstrated substantial clinical efficacy in homologous recombination repair (HRR)/DNA damage response (DDR)-altered metastatic castration-resistant prostate cancers (mCRPC). Phase III study results (de Bono et al. N Engl J Med. 2020;382:2091-2102) led to the approval of olaparib for mCRPC. ENZA is an androgen receptor (AR) inhibitor and established therapy for mCSPC.